ARGX argenx SE
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 9-month channel rising
Price is between the lines.
- 9-month channel read from
- US$793.33 – US$1,222 · rising, +39% a year
- 12-month channel
- US$792.98 – US$935.71 · rising, +11% a year
- Price in channel
- 23% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$935.71
- Turns bearish below
- US$793.33
What broke this trend
- The fall
- -24% from US$1,05927 Aug 2026 → 13 Oct 2026
- Whose problem it was
- This company2 of 7 Biotechnology peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 37%of what it lost
- What the record says
- 94% of 15 comparable falls came back, typically in 39 days measured on its own peer group
Fell -24% (27 Aug 2026 → 13 Oct 2026); regained 37% so far; company-specific.
Buy and target use the recovery path, not the channel.
Reported at the time: Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415 — 26 Aug 2026
Price history, with the path projected 3 months forward
Updated 2:22 AM ET (58 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$892.59
last close · 30 Oct 2026
Our target
US$1,072
by 6 Dec 2026
Projected move
20.1%
gross, before costs
Last close is our buy.
Target: recovery of the recent fall.
This move size: reached in 20% of 10 past stretches, typically in 35 days. (0.56% per day)
- Upper line touches
- 3
- Lower line touches
- 2
- Fit confidence
- 46%
- Fitted
- 1 Nov 2026
Company information
About argenx SE
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Massey
- Employees
- 1,863
- Country
- NL
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$58.46B
- Enterprise value
- —
- Beta
- -0.02
- Avg volume
- 306.89K
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 661.85-1072.75
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.